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Preliminary and Short Report
THIABENDAZOLE ACTIVITY AGAINST THE FUNGI OF DERMATOPHYTOSIS
MYCETOMAS AND CHROMOMYCOSIS*
HARVEY BLANK, M.D. AND GERBERT REBELL, MS.
Recently the anthelminthic compound 2(4'thia-
zolyl)-benzimidazole (thiabendazole—Merck Sharp
and Dohme) was reported to be active against
some pathogenic fungi (1). In our laboratory we
have confirmed the original report, and also tested
thiabendazole against additional fungi.
Assays were performed both in Sabouraud dex-
Stock solutions containing 10 mg/ml of thia-
bendazole were made in 0.1 N HC1, sterilized by
Millipore filtration, diluted and added after auto-
claving of the media. Serial dilutions were pre-
pared so that each final assay tube with a volume
of 4 ml contained 0.001 N HC1 and an appropriate
dilution of thiabendazole.
TABLE I
Microsporum canis
M. audouinii
M. ferrugineum
M. gypseum
Trichophyton mentagrophytes
(zoophilic form)
T. verrucosum
T. gallinae
T. rubrum (fluffy form)
T. tonsurans
T. violaceum
T. soudanense
T. yaoundei
T. schoenleinii
T. concentricum
Epidermophyton floccosum
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Roth P2049
UM 2B2
CDC X-558
UM 3A1
UM 1A2
CDC R-23
CDC A-b
Roth P2080
UM 1B12
UM1B15
Roth P2132
CDC X-496
CDC B-430
UM iLl
Roth P2121
CDC B-64
UM 2A3
x
x
x
x
x
x
x
x
x
x
trose broth (Difco) incubated on a roller drum
apparatus and on Sabouraud dextrose agar (Difco)
slanted in tubes. The media were prepared with
the addition of 0.5% yeast extract (Bacto) and
sterilized in the autoclave.
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Fungus inocula were prepared by lightly grind-
ing a portion of a surface colony, grown on
Sabouraud dextrose agar, in a Tenbroeck glass
homogenizer with 0.5 ml of Sabouraud dextrose
broth, diluting to 2.5 ml, and inoculating each
tube with 0.1 ml of this suspension. No attempt
was made to precisely quantitate the fungus
inocula.
The tubes were incubated at room temperature(26°C.) and examined daily for first signs of
growth. Incubation was continued until maximum
growth was obtained and no further changes in
the endpoint of inhibition occurred.
Most endpoints were observed to be clearcut
Species Culture No.
Minimum Inhibitory Concentration of Thiabendazole
2.5 g/ml 0.5—2.0 g/ml less than 0.5 g/ml
x
x
x
x
x
x
x
Culture designations: Roth, F. J. Roth, Department of Microbiology, University of Miami School of
Medicine; UM, Department of Dermatology, University of Miami School of Medicine; CDC, Mycology
Unit, Communicable Disease Center, US Department of Health, Education and Welfare, Atlanta,
Georgia.
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TABLE II
Activity of thiabendazole against miscellaneous pathogenic fungi in vitro
Species Culture No. Minimuiitoyconcentration
Cladosporium bantianum CDC 94 0.75
Cladosporium carrionii UM 25C2 0.75
Phialophora verrucosa Roth P2471 0.75
Phialophora jeanselmei CDC 96 0.75
Fonsecaea pedrosoi Roth P2440 0.75
Fonsecaea compacturn Roth P2430 0.75
Madurella mycetomii CDC 98 0.75
Madurella grisea Borelli 3528 0.75
Pyrenochaeta romeroi Borelli 151 0.75
Leptosphaera senegalensis CDC B-525 0.75
Fusarium sp. (keratitis) UM 32A1 6.2
Aspergillus fumigatus Roth P2049 12.5 agar
>100 broth
Hyalopus falciforme Borelli 115 50 agar
100 broth
Nocardia cavidae UM 14C1 >100
Basidiobolus ranarurn CDC B-530 >100
Curvularia sp. (equine mycetoma) UM 33A1 >100
Allescheria boydii Roth P2231
UM2A3
>100
>100
Streptomyces madurae CDC 89 >100
Culture designations: See Table I; Borelli, D. Borelli, Institute of Tropical Medicine, Caracas,
Venezuela.
after ten days' incubation. Only trivial differences
between the endpoints in broth and agar were
observed. In these instances inhibition occurred at
a lower concentration of drug in agar; and may
have been due to a growth ring which sometimes
occurred on the glass of the roller tube prepara-.
tions above the level of effective contact with the
media.
In the results summarized in Tables 1 and
2, the endpoint in agar is given where a difference
occurred.
An attempt was also made to demonstrate ac-
quired resistance to the compound by successive
transfer of T. mentagrophytes (IJM 1A2) at
thirty-day intervals through successive transfers
in media containing 0.78 g/ml thiabendazole.
No change in endpoint was observed at this
partially inhibitory concentration after continu-
ous growth.
5UMMARY
1. Our results confirm the findings of Robinson,
Phares and Grassle, indicating significant in vitro
activity of thiabendazole against dermatophytes.
2. Species of Cladosporium, Phialophora, Fon-
secaea, Madurella, Pyrenochaeta, Leptosphaera
and possibly Fusarium and Aspergillus are also
inhibited by the drug.
3. Clinical trials, by oral administration of the
drug would seem warranted for the treatment of
subcutaneous infections such as eumycotic my-
cetomas and chromomycosis, as well as for diseases
caused by some opportunistic fungi. The possible
topical use of thiabendazole in the eye and on the
skin would also seem to merit consideration.
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